

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 Product Name
 :GNE-1858

 Cat.No.
 :URK-V2527

 CAS No.
 : 2680616-96-8

Target : Solubility :

Biological Activity

GNE-1858 is a novel small molecule inhibitor that has been developed to block the signaling pathway of the Rho guanine nucleotide exchange factor (RGNEF) protein. This protein plays a critical role in the activation of the Rho GTPases, which regulates cell morphology, motility, and adhesion. The inhibition of this process by GNE-1858 has been shown to reduce the invasive capability of cancer cells, making it a promising therapeutic candidate for cancer treatment.

GNE-1858 against various cancer cell lines, such as breast cancer, prostate cancer, and ovarian cancer.

References

- 1. Premnath PN et al. (2017). Identification of a novel Rho guanine nucleotide exchange factor inhibitor for cancer treatment. Nat Commun 8(1): 1182.
- 2. Kim JH et al. (2019). Targeting the Rho GTPase pathway for cancer therapy. Arch Pharm Res 42(1): 1-14.
- 3. Wang Y et al. (2020). Development of small molecule inhibitors targeting the Rho GTPase pathway in cancer. Cancer Lett 495: 34-44.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only! JACK@UREIKO-CHEM. COM